Dana Investment Advisors Inc. lowered its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 99,631 shares of the company's stock after selling 5,758 shares during the period. Dana Investment Advisors Inc. owned approximately 0.20% of Prestige Consumer Healthcare worth $7,780,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also modified their holdings of the company. Martingale Asset Management L P raised its position in Prestige Consumer Healthcare by 0.4% during the 3rd quarter. Martingale Asset Management L P now owns 36,971 shares of the company's stock valued at $2,666,000 after purchasing an additional 140 shares in the last quarter. Horizon Kinetics Asset Management LLC increased its stake in shares of Prestige Consumer Healthcare by 4.8% during the third quarter. Horizon Kinetics Asset Management LLC now owns 3,247 shares of the company's stock valued at $234,000 after buying an additional 150 shares during the period. QRG Capital Management Inc. increased its stake in shares of Prestige Consumer Healthcare by 3.3% during the fourth quarter. QRG Capital Management Inc. now owns 5,496 shares of the company's stock valued at $429,000 after buying an additional 176 shares during the period. Huntington National Bank raised its holdings in shares of Prestige Consumer Healthcare by 39.9% in the third quarter. Huntington National Bank now owns 635 shares of the company's stock valued at $46,000 after acquiring an additional 181 shares in the last quarter. Finally, GAMMA Investing LLC lifted its stake in Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock worth $108,000 after acquiring an additional 220 shares during the period. Hedge funds and other institutional investors own 99.95% of the company's stock.
Prestige Consumer Healthcare Stock Up 2.3 %
NYSE:PBH traded up $2.01 during midday trading on Friday, reaching $89.10. 604,737 shares of the stock traded hands, compared to its average volume of 328,521. The stock has a market capitalization of $4.41 billion, a PE ratio of 20.87, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. Prestige Consumer Healthcare Inc. has a 12-month low of $62.35 and a 12-month high of $89.65. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. The business has a 50-day moving average of $80.80 and a two-hundred day moving average of $77.83.
Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 EPS for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. On average, equities analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have commented on PBH. Raymond James raised shares of Prestige Consumer Healthcare to a "moderate buy" rating in a research report on Thursday, December 19th. Sidoti lowered shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. StockNews.com upgraded Prestige Consumer Healthcare from a "hold" rating to a "buy" rating in a report on Friday, January 24th. Oppenheimer lifted their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the company an "outperform" rating in a report on Thursday, February 13th. Finally, DA Davidson boosted their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $92.60.
View Our Latest Research Report on Prestige Consumer Healthcare
Prestige Consumer Healthcare Profile
(
Free Report)
Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.
Further Reading
Before you consider Prestige Consumer Healthcare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prestige Consumer Healthcare wasn't on the list.
While Prestige Consumer Healthcare currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
